Skip to main content

View Resource

Published

Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
Chalkias S. The Lancet Infectious Diseases 2025;:doi: 10.1016/S1473-3099(25)00236-1.
[We evaluated the relative vaccine efficacy (rVE), immunogenicity, and safety of mRNA-1283 compared to the first-generation vaccine (mRNA-1273). mRNA-1283 was well-tolerated. The rVE and immunogenicity non-inferiority criteria were met, with higher antibody responses for mRNA-1283 versus mRNA-1273. The potential clinical benefit of mRNA-1283 versus mRNA-1273 needs to be confirmed in post-marketing evaluation.]
Contact the library for a copy of this article
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Community Clinics
General Practice
Hospital Laboratories
Outpatient Department
Population Health
Staff Groups
Biomedical Scientist
Clinical Scientist
Drug Therapy
Immunisation
Medic
Pharmacist